The FDA approved Friday September 18, 2026 Eli Lilly's (NYSE: LLY) Inluriyo (imlunestrant, oral next-generation selective estrogen receptor degrader / SERD) in combination with Verzenio (abemaciclib, oral CDK4/6 inhibitor) for adults with estrogen-receptor-positive (ER+), HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease progressed after at least one prior line of endocrine therapy. ESR1 mutations are detected via the FDA-authorized Guardant360 CDx companion diagnostic (Guardant Health, NASDAQ: GH). Patients on the combination had median progression-free survival of 11.1 months versus 5.5 months on Inluriyo monotherapy — an approximately 2× improvement. This is Inluriyo's second FDA approval within a year after its September 2025 monotherapy approval in the same population and is the first FDA-approved oral-SERD + CDK4/6 inhibitor combination in this setting. The approval strengthens Lilly's breast-cancer franchise anchored by Verzenio ($6.3B 2025 global sales) and expands the addressable population for both agents.
BMO Capital Markets published a Thursday September 17, 2026 morning analyst note reading Eli Lilly's (NYSE: LLY) TRIUMPH Phase 3 program readouts for retatrutide (once-weekly subcutaneous injectable triple-hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors) as positive for retatrutide's efficacy and benefit-risk profile. TRIUMPH-2 evaluates retatrutide in adults with obesity or overweight plus type 2 diabetes; TRIUMPH-3 evaluates retatrutide in adults with severe obesity plus established cardiovascular disease. TRIUMPH-3 topline reported in July 2026 documented an average 22.6% body weight reduction at 80 weeks at the highest dose. TRIUMPH-1 (the base obesity indication, reported May 2026) documented up to 28.3% mean weight loss at 80 weeks. Lilly guided to a Q1 2027 Biologics License Application (BLA) filing across obesity, obstructive sleep apnea, and knee osteoarthritis pain, deferred from the prior late-2026 timeline. Retatrutide would be the first triple hormone receptor agonist to reach FDA review; its efficacy exceeds tirzepatide (Zepbound/Mounjoro, 20.2% in SURMOUNT-5 vs Wegovy 13.7% at 72 weeks) and semaglutide (Wegovy 13.7% same trial) by clinically relevant margins.
The oral GLP-1 launch race entered its ninth month with Novo Nordisk's Wegovy pill (oral semaglutide 25/50 mg for chronic weight management, U.S. launch January 5, 2026) reaching approximately 183,000 weekly total scripts per the most recent IQVIA week ending September 5, 2026 — the highest weekly total since launch. Eli Lilly's Foundayo (orforglipron, once-daily oral small-molecule non-peptide GLP-1 receptor agonist, U.S. launch April 2026) continued its own prescription climb through the same reporting window. Both products are indicated for adults with obesity or overweight with weight-related comorbidities. Wegovy pill's climb reflects continued Medicare Part D coverage expansion following the November 2025 pricing agreement (Ozempic Pill / Wegovy pill at $149/month per the deal) and CMS 2026 formulary guidance. Foundayo pricing on TrumpRx and cash-pay LillyDirect anchors at $149/month at starting doses. The concurrent oral launch trajectories are the largest test to date of oral incretin adoption relative to the established weekly-injectable class dominated by injectable Wegovy and Zepbound.
Eli Lilly (NYSE: LLY) continued rollout through September 2026 of the early-access program for retatrutide (a once-weekly subcutaneous injectable GIP/GLP-1/glucagon triple agonist peptide for obesity) ahead of the Q1 2027 BLA submission plan confirmed after the July 23, 2026 TRIUMPH-2 and TRIUMPH-3 Phase 3 wins in obesity plus type 2 diabetes and obesity plus established cardiovascular disease. The 12 mg retatrutide dose produced 28.3% mean weight loss at 80 weeks in the TRIUMPH-1 Phase 3 obesity monotherapy trial reported in May 2026, the highest weight loss reported for any obesity therapy in a Phase 3 setting. TRIUMPH-4 (knee osteoarthritis, 68 weeks) added 28.7% weight loss plus improvements in pain and physical function. Seven Phase 3 readouts total are expected across the retatrutide program in 2026. Lilly management has framed retatrutide as the successor commercial franchise to Zepbound and Mounjaro, with launch anticipated 2027-2028 under the Most Favored Nation pricing framework that would apply from initial approval per the November 2025 pricing agreement.
H1 2026 GLP-1 franchise reporting places Eli Lilly (NYSE: LLY) tirzepatide (Mounjaro plus Zepbound) at nearly $27.7 billion in first-half revenue, an 88% year-over-year increase, versus Novo Nordisk (NYSE: NVO) semaglutide (Ozempic plus Wegovy plus Rybelsus plus Wegovy pill) at approximately $17.5 billion. The revenue gap between the two GLP-1 leaders has widened from under $2 billion at the same point last year to $10.2 billion, driven by Zepbound share gains in U.S. obesity following SURMOUNT-5 superiority data over Wegovy, Mounjaro upside in international markets (China +93% CER, Rest of World +136%), Foundayo (orforglipron) first commercial quarter contribution of $98 million, and semaglutide patent expiries approaching in select markets (generic Ozempic expected in Canada). Novo has cut 12,000 positions in H1 2026 and lowered gross margin outlook to 78%, while Lilly raised full-year 2026 revenue guidance to $85-87 billion.
Eli Lilly (NYSE: LLY) clarified that the retatrutide (once-weekly injectable GIP/GLP-1/glucagon triple agonist peptide) regulatory submission timeline was pushed from end-2026 to Q1 2027 as the company continues gathering manufacturing and quality control data required for the FDA Biologics License Application. TRIUMPH-1 (obesity without type 2 diabetes) Phase 3 readout updated documented 28.3% mean weight loss at 80 weeks on the 12 mg weekly injection arm in 2,339 participants, the largest weight-loss figure reported in any Phase 3 obesity trial to date. Combined with TRIUMPH-2 (obesity plus type 2 diabetes at up to 20.8% weight loss and 1.6 percentage point HbA1c reduction in 1,152 participants), TRIUMPH-3 (additional confirmatory data), and TRIUMPH-4 (obesity plus knee osteoarthritis at 28.7% weight loss and 75.8% WOMAC pain reduction), the retatrutide package now anchors four major indication frames. Additional TRIUMPH readouts expected across 2026 in obstructive sleep apnea, chronic lower back pain, and cardio-renal-metabolic outcomes will strengthen the label breadth. The Q1 2027 filing timeline shift is a modest delay from prior end-2026 signaling but reflects manufacturing-scale challenges typical of peptide APIs at the projected multi-billion-dollar commercial demand level (semaglutide and tirzepatide combined are already at roughly $80 billion annual revenue). Potential FDA approval expected in 2027 to 2028 following the standard 10-month review or 6-month priority review if a Priority Review Voucher (PRV) is deployed. Retatrutide will likely reshape the entire obesity drug class ceiling on the injectable side once approved.
Eli Lilly (NYSE: LLY) plans to submit a Biologics License Application (BLA) for retatrutide (once-weekly injectable GIP/GLP-1/glucagon triple hormone receptor agonist peptide) to the FDA in Q1 2027 following the July 23, 2026 TRIUMPH-2 and TRIUMPH-3 Phase 3 readouts. TRIUMPH-2 (obesity and type 2 diabetes) enrolled 1,152 adults and documented up to 20.8% mean weight loss and 1.6 percentage point HbA1c reduction at 68 weeks. TRIUMPH-3 confirmed similar efficacy profiles across an additional patient population. Combined with the earlier readouts (TRIUMPH-1 in obesity without diabetes at 28.7% mean weight loss at 68 weeks at the 12 mg dose, and TRIUMPH-4 in obesity plus knee osteoarthritis at 28.7% weight loss with 75.8% reduction in WOMAC pain scores), the retatrutide package now covers four major indication frames with consistent efficacy. Additional TRIUMPH readouts expected across 2026 in obstructive sleep apnea, chronic lower back pain, and cardio-renal-metabolic outcomes will strengthen the label breadth. Potential FDA approval is expected in 2027-2028, positioning retatrutide to set the new weight-loss ceiling in the obesity drug class at 28.7% (versus tirzepatide's 25.5% and semaglutide's 15% in the current approved landscape).
Eli Lilly (NYSE: LLY) is expected to submit retatrutide (once-weekly injectable triple GLP-1/GIP/glucagon receptor agonist peptide) to the FDA in late 2026 or 2027 following the seven Phase 3 TRIUMPH-program readouts expected across 2026. Program status: TRIUMPH-1 in obesity met primary endpoint with 28.7% mean weight loss at 68 weeks at the 12 mg dose; TRIUMPH-4 in obesity plus knee osteoarthritis documented 28.7% weight loss and 75.8% reduction in WOMAC pain scores with more than 1 in 8 retatrutide-treated patients completely free from knee pain at study end. Additional Phase 3 readouts expected across 2026 in type 2 diabetes, obstructive sleep apnea, chronic lower back pain, and cardio-renal-metabolic indications. If the full TRIUMPH package supports approval, retatrutide would be the highest-magnitude weight loss obesity drug on record (extending the ceiling from tirzepatide's 25.5% at 84 weeks in REDEFINE 4 head-to-head to 28.7% in TRIUMPH-4). The triple-receptor mechanism activates GLP-1 (appetite suppression via hypothalamic pathways), GIP (adipose tissue effects plus central appetite contribution), and glucagon (hepatic effects plus thermogenesis), producing broader tissue coverage than dual-agonist tirzepatide or amylin-plus-GLP-1 CagriSema. Approval is anticipated in 2027-2028 and would reshape the competitive dynamics for the entire obesity drug class, with substantial implications for Novo Nordisk's franchise defense strategy following the August 2026 broker downgrade and Wegovy 7.2 mg higher-dose FDA review submission.
Novo Nordisk (NYSE: NVO) shares fell approximately 6% Thursday August 13, 2026 on broker downgrade citing continued franchise-gap pressure from Eli Lilly's tirzepatide franchise (Mounjaro + Zepbound) and the CagriSema head-to-head miss against tirzepatide. Specifics: CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg fixed-dose combination) reached 23.0% weight loss at 84 weeks versus tirzepatide 15 mg's 25.5% in the REDEFINE 4 head-to-head Phase 3 trial published in early August 2026. The August 4 H1 2026 earnings release raised full-year 2026 sales guidance to down 3% from a prior down 8% midpoint at constant exchange rates. The broader investor narrative continues to focus on Novo's ability to defend GLP-1 franchise economics against Eli Lilly's Q2 2026 $23 billion revenue blowout (+48% year-over-year), Foundayo (orforglipron) $98 million first commercial quarter, and retatrutide's 28.7% Phase 3 TRIUMPH-4 weight loss result at 68 weeks. Analyst attention now shifts to Novo's Wegovy 7.2 mg higher-dose FDA review, the amycretin oral amylin monotherapy Phase 1b program (roughly 22% weight loss at Week 36), and next-generation candidates in Novo's pipeline. Investors are also watching the CagriSema FDA decision expected late 2026 and whether the label expansion strategy can offset the competitive pressure.
Eli Lilly (NYSE: LLY) reported Q2 2026 earnings Wednesday August 5, 2026 with revenue of $23 billion (+48% year-over-year), well ahead of analyst consensus of $20.5 billion. Full-year 2026 revenue guidance was raised to $85-87 billion from the prior $82-85 billion range. Mounjaro (tirzepatide for type 2 diabetes) revenue rose 91% to $9.9 billion, split $4.8 billion US and $5.2 billion international, with the international majority driven by aggregate international Mounjaro market share now above 50% per prior Lilly executive commentary. Zepbound (tirzepatide for obesity) delivered $4.9 billion in US revenue (+44% year-over-year), with strong prescription-volume growth more than offsetting the low-to-mid-teens price erosion Lilly had guided to for FY26. Foundayo (orforglipron, the first oral small-molecule GLP-1 receptor agonist approved by FDA in April 2026) generated $98 million in its first fully operational commercial quarter, providing the first commercial-earnings-line view of the oral small-molecule GLP-1 category. Combined Mounjaro + Zepbound franchise revenue reached $14.9 billion, representing approximately 65% of total Lilly revenue for the quarter. LLY shares rose approximately 4% intraday on the earnings and guidance beat. Analyst commentary flagged the substantial widening of the Lilly-Novo obesity franchise gap.
Eli Lilly (NYSE: LLY) reports Q2 2026 earnings Wednesday August 5, 2026 before market open with analyst consensus at $20.5 billion revenue and $7.74 EPS. Primary analyst focus numbers: Foundayo (orforglipron) weekly prescription volumes near 20,000 as the initial commercial ramp indicator following the April 2026 FDA approval as the first oral small-molecule non-peptide GLP-1 receptor agonist; Mounjaro (tirzepatide, type 2 diabetes indication) and Zepbound (tirzepatide, obesity indication) sales trajectory (Q1 2026 combined revenue $12.82 billion, approximately 65% of Lilly total revenue, driven by U.S. commercial volume plus international expansion with aggregate international Mounjaro market share now north of 50% per Lilly executive commentary at Goldman Sachs Healthcare Conference); full-year 2026 revenue guidance currently at $83-85 billion for potential revision; and the international pricing pressure headwind with management guiding low-to-mid-teens price erosion for FY26. Novo Nordisk reports H1 2026 results the same Wednesday August 5. Wegovy pill (oral semaglutide 25/50 mg for obesity) Q1 2026 sales of approximately $354 million provide the H1 baseline for the Novo pill franchise; injectable Wegovy Q1 2026 sales were $18.2 billion Danish kroner (+12% YoY).
Novo Nordisk announced Friday July 24, 2026 that it has filed for a temporary restraining order (TRO) and preliminary injunction in the US District Court for the District of New Jersey to immediately block Eli Lilly's national Zepbound (tirzepatide) and Mounjaro (tirzepatide) direct-to-consumer advertising campaigns. The escalation comes three business days after Novo's original complaint filed Tuesday July 21 alleging that Lilly's ads rely on outdated Wegovy (semaglutide) dose comparisons that do not account for the newer, higher-dose FDA-approved semaglutide options currently available. Through the TRO and preliminary injunction motions, Novo Nordisk seeks immediate court-ordered removal of the disputed Lilly campaigns pending a full merits ruling on the underlying deceptive-advertising claims. Novo also seeks a permanent injunction requiring Lilly to pull all misleading comparative advertising across platforms and to conduct a corrective advertising campaign. The GLP-1 ad war has moved from network TV pharmacy-facing PBM negotiation into full federal court litigation for the first time in the class's US commercialization history. Court hearing dates on the TRO/preliminary injunction have not yet been reported publicly.